Overview:
Prostate cancer remains a major clinical challenge, particularly in advanced stages where treatment decisions are increasingly complex. PSMA-targeted imaging and radioligand therapies offer new opportunities to improve outcomes, but gaps remain in clinician understanding of patient selection, treatment sequencing, and multidisciplinary coordination.
This 2-hour hybrid tumor board symposium will be held during the 2025 ASTRO Annual Meeting in San Francisco, CA. Through expert-led case discussions and interactive audience participation, the program will address key decision points in integrating PSMA imaging and targeted therapies.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Explain the diagnostic and prognostic significance of PSMA PET/CT in prostate cancer and interpret imaging findings to guide radiotherapy planning and clinical decision-making.
- Assess recent clinical evidence for PSMA-targeted radioligand therapies and define the role of radiation oncology in their delivery, monitoring, and coordination.
- Design patient-centered strategies for incorporating PSMA-directed radioligand therapy into care pathways, including sequencing and coordination with other specialties.
- Identify institutional and logistical barriers to radioligand therapy delivery and propose solutions to expand access.
This activity is supported by educational grants from Blue Earth Diagnostics; Lantheus; and Novartis Pharmaceuticals Corporation.
PER is proud to partner with ZERO Prostate Cancer.
